Elaine R Mardis from the Nationwide Children’s Hospital & Ohio State University College of Medicine, OH, US, and AACR President-Elect (2018–2019), talks to us about her upcoming role and how AACR aims to meet unmet needs in cancer research and personalized medicine in the future.
1. What are the main aims of the American Association for Cancer Research (AACR)? (0:08)
2. What do you anticipate to be the major challenges of your role as president of the AACR? (0:31)
3. What have been the most exciting developments in the genomic characterization of cancer in the past year? (1:35)
4. What are the major unmet needs in personalized cancer medicine? (2:19)
5. What do you expect to be the key themes of the AACR annual meeting? (3:24)Speaker disclosures: Elaine R Mardis has nothing to disclose in relation to this video interview.
Filmed at the American Association for Cancer Research (AACR) Annual Meeting 2018, Chicago, IL, US, April 14–18, 2018.
Related Videos In Haematological Malignancies
María-Victoria Mateos, EHA 2020: TOURMALINE-MM4 study
Dr María-Victoria Mateos, (Associate Professor of Medicine, Director of Myeloma Unit, University Hospital of Salamanca, Salamanca, Spain) explores unmet needs in the treatment of patients with newly-diagnosed multiple myeloma, and discusses the major findings of the TOURMALINE-MM4 study and the potential of ixazomib in patients no undergoing autologous stem cell transplant. Questions: What are the limitations […]
Courtney DiNardo, EHA 2020: Venetoclax plus Azacitadine in AML and the VIALE-A Study
Dr Courtney DiNardo (The University of Texas MD Anderson Cancer Center, Houston, United States) joins touchONCOLOGY to discuss the key findings from the VIALE-A study and the safety and efficacy of venetoclax plus azacitadine in patients with acute myeloid leukaemia and (NCT02203773 and NCT02287233.) Questions 1. What are the limitations of current therapeutic options for […]
Mikkael Sekeres, ASCO20: New combination therapy in patients with MDS/CMML or LB AML
It was a pleasure to speak to Mikkael Sekeres to discuss the presentation of the phase II study of pevonedistat + azacitidine versus azacitidine in patients with higher-risk myelodysplastic syndromes/chronic myelomonocytic leukemia, or low-blast acute myelogenous leukemia (Clinicaltrials.gov identifier: NCT02610777). Questions 1. What are the limitations of hypomethylating agents such as, 5-azacitidine in the treatment […]
Journal articles and more to your inbox
Get the latest clinical insights from touchONCOLOGYSign me up!